Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Aspirin suppresses PGE2 and activates AMP kinase to inhibit melanoma cell motility, pigmentation and selective tumor growth in vivo.

Kumar D, Rahman H, Tyagi E, Liu T, Li C, Lu R, Lum D, Holmen SL, Maschek JA, Cox JE, VanBrocklin MW, Grossman D.

Cancer Prev Res (Phila). 2018 Jul 18. pii: canprevres.0087.2018. doi: 10.1158/1940-6207.CAPR-18-0087. [Epub ahead of print]

PMID:
30021726
2.

Mutant IDH1 Promotes Glioma Formation In Vivo.

Philip B, Yu DX, Silvis MR, Shin CH, Robinson JP, Robinson GL, Welker AE, Angel SN, Tripp SR, Sonnen JA, VanBrocklin MW, Gibbons RJ, Looper RE, Colman H, Holmen SL.

Cell Rep. 2018 May 1;23(5):1553-1564. doi: 10.1016/j.celrep.2018.03.133.

3.

Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.

Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW.

Melanoma Res. 2017 Dec;27(6):545-557. doi: 10.1097/CMR.0000000000000403.

PMID:
29076949
4.

In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation.

Robinson GL, Philip B, Guthrie MR, Cox JE, Robinson JP, VanBrocklin MW, Holmen SL.

Cancer Res Front. 2016 May;2(2):311-329. doi: 10.17980/2016.311. Epub 2016 Jul 9.

5.

HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss.

Shin CH, Robinson JP, Sonnen JA, Welker AE, Yu DX, VanBrocklin MW, Holmen SL.

Oncogene. 2017 Aug 10;36(32):4610-4618. doi: 10.1038/onc.2017.83. Epub 2017 Apr 3.

6.

Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.

Yang H, Kircher DA, Kim KH, Grossmann AH, VanBrocklin MW, Holmen SL, Robinson JP.

Oncogene. 2017 Jul 6;36(27):3842-3851. doi: 10.1038/onc.2016.526. Epub 2017 Mar 6.

7.

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma.

Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT.

Oncotarget. 2016 Sep 27;7(39):64390-64399. doi: 10.18632/oncotarget.10453.

8.

AKT1 Activation Promotes Development of Melanoma Metastases.

Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL.

Cell Rep. 2015 Nov 3;13(5):898-905. doi: 10.1016/j.celrep.2015.09.057. Epub 2015 Oct 22.

9.

Model of the TVA receptor determinants required for efficient infection by subgroup A avian sarcoma and leukosis viruses.

Melder DC, Pike GM, VanBrocklin MW, Federspiel MJ.

J Virol. 2015 Feb;89(4):2136-48. doi: 10.1128/JVI.02339-14. Epub 2014 Dec 3.

10.

Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss.

Robinson GL, Robinson JP, Lastwika KJ, Holmen SL, Vanbrocklin MW.

Genes Cancer. 2013 Nov;4(11-12):476-85. doi: 10.1177/1947601913513268.

11.

Ink4a/Arf loss promotes tumor recurrence following Ras inhibition.

Vanbrocklin MW, Robinson JP, Lastwika KJ, McKinney AJ, Gach HM, Holmen SL.

Neuro Oncol. 2012 Jan;14(1):34-42. doi: 10.1093/neuonc/nor184. Epub 2011 Oct 20.

12.

Akt signaling is required for glioblastoma maintenance in vivo.

Robinson JP, Vanbrocklin MW, McKinney AJ, Gach HM, Holmen SL.

Am J Cancer Res. 2011;1(2):155-167.

13.

Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.

Robinson JP, Vanbrocklin MW, Lastwika KJ, McKinney AJ, Brandner S, Holmen SL.

Oncogene. 2011 Mar 17;30(11):1341-50. doi: 10.1038/onc.2010.513. Epub 2010 Nov 8.

14.

Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice.

VanBrocklin MW, Robinson JP, Lastwika KJ, Khoury JD, Holmen SL.

Pigment Cell Melanoma Res. 2010 Aug;23(4):531-41. doi: 10.1111/j.1755-148X.2010.00717.x. Epub 2010 Apr 23.

15.

Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation.

Robinson JP, VanBrocklin MW, Guilbeault AR, Signorelli DL, Brandner S, Holmen SL.

Oncogene. 2010 Jan 21;29(3):335-44. doi: 10.1038/onc.2009.333. Epub 2009 Oct 26.

16.

Met amplification and tumor progression in Cdkn2a-deficient melanocytes.

Vanbrocklin MW, Robinson JP, Whitwam T, Guilbeault AR, Koeman J, Swiatek PJ, Vande Woude GF, Khoury JD, Holmen SL.

Pigment Cell Melanoma Res. 2009 Aug;22(4):454-60. doi: 10.1111/j.1755-148X.2009.00576.x. Epub 2009 Apr 29.

17.

Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma.

VanBrocklin MW, Verhaegen M, Soengas MS, Holmen SL.

Cancer Res. 2009 Mar 1;69(5):1985-94. doi: 10.1158/0008-5472.CAN-08-3934. Epub 2009 Feb 24.

18.

Inhibition of avian leukosis virus replication by vector-based RNA interference.

Chen M, Granger AJ, Vanbrocklin MW, Payne WS, Hunt H, Zhang H, Dodgson JB, Holmen SL.

Virology. 2007 Sep 1;365(2):464-72. Epub 2007 May 9.

19.

Differential oncogenic potential of activated RAS isoforms in melanocytes.

Whitwam T, Vanbrocklin MW, Russo ME, Haak PT, Bilgili D, Resau JH, Koo HM, Holmen SL.

Oncogene. 2007 Jul 5;26(31):4563-70. Epub 2007 Feb 5.

PMID:
17297468
20.
21.

Efficient lipid-mediated transfection of DNA into primary rat hepatocytes.

Holmen SL, Vanbrocklin MW, Eversole RR, Stapleton SR, Ginsberg LC.

In Vitro Cell Dev Biol Anim. 1995 May;31(5):347-51.

PMID:
7633672

Supplemental Content

Loading ...
Support Center